References
- Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
- Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:290–293.
- Agis H, Sotlar K, Valent P, . Ph-chromosome-positive chronic myeloid leukemia with associated bone marrow mastocytosis. Leuk Res 2005;29:1227–1232.
- Shtivelman E, Lifshitz B, Gale RP, . Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature 1985;315:550–554.
- Puil L, Liu J, Gish G, . Bcr-abl oncoproteins bind directly to activators of the ras signalling pathway. EMBO J 1994;13:764–773.
- Gordon MY, Dowding CR, Riley GP, . Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987;328:342–344.
- Bedi A, Zehnbauer BA, Barber JP, . Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood 1994;83:2038–2044.
- Cortes J, O'Dwyer ME. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:671–684.
- Weisberg E, Manley PW, Breitenstein W, . Characterization of AMN107, a selective inhibitor of native and mutant bcr-abl. Cancer Cell 2005;7:129–141.
- Kantarjian HM, Giles FJ, Bhalla KN, . Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase following imatinib resistance or intolerance: 24-month follow-up results. Blood 2011;117:1141–1145.
- le Coutre P, Giles F, Hochhaus A, . Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: longer follow-up results of a phase II study. J Clin Oncol 2009;27(15 Suppl.): Abstract 7057.
- Giles FJ, Kantarjian H, le Coutre PD, . Use of nilotinib to induce responses with 24-month (mo) minimum follow-up in patients (pts) with chronic myeloid leukemia in blast crisis (CML-BC) resistant to or intolerant of imatinib. J Clin Oncol 2010;28(15 Suppl.): Abstract 6510.
- Saglio G, Kim DW, Issaragrisil S, . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010;362:2251–2259.
- Nicolini FE, Turkina A, Shen ZX, . Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase. Cancer 2011 Jul 5 [Epub ahead of print]
- Kantarjian H, Giles F, Wunderle L, . Nilotinib in imatinib-resistant CML and philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542–2551.
- Chugh SS, Jui J, Gunson K, . Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community. J Am Coll Cardiol 2004;44:1268–1275.
- Kantarjian H, O'Brien S, Talpaz M, . Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer 2007;109:1556–1560.